澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BCAL DIAGNOSTICS LTD

0.077

+0.00710.00%

成交量：9,573

成交額：737

市值：2,834.12萬

市盈率：-3.84

高：0.077

開：0.077

低：0.077

收：0.070

52周最高：0.155

52周最低：0.052

股本：3.68億

流通股本：2.02億

量比：0.78

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.020

每股收益(LYR):-0.020

淨資產收益率：-273.29%

總資產收益率：-50.29%

市淨率：-34.30

市盈率(LYR):-3.85

資料載入中...

總覽公司新聞資訊公告

BCAL Diagnostics澄清：未與GSS或MAP進行任何併購談判或提案往來

BCAL Diagnostics：文中所引述言論源自部分主張三方合併的基金管理人之觀點

BCAL診斷公司：要求罷免Michael Aicher，並提名Forrester與Melki進入GSS董事會

遺傳特徵公司要求BCAL診斷澄清其在GSS的持股及關聯方詳情

BCAL Diagnostics將收購Genetic Signatures股份

BCAL診斷公司與Sonic Healthcare USA或就驗證後的Breastestplus V2版本商談商業許可

BCAL Diagnostics Ltd 提交Avantect胰腺癌早期檢測血液測試的MSAC申請

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BDX.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.077,"timestamp":1789606054022,"preClose":0.07,"halted":0,"volume":9573,"delay":0,"changeRate":0.09999999999999988,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":368067640,"eps":-0.020055,"marketStatus":"交易中","change":0.007,"latestTime":"09-17 10:53:12 AEST","open":0.077,"high":0.077,"low":0.077,"amount":737,"amplitude":0,"askPrice":0.077,"askSize":302,"bidPrice":0.075,"bidSize":15970,"shortable":3,"etf":0,"ttmEps":-0.020055,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789624800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.07,"openAndCloseTimeList":[[1789603200000,1789624800000]],"volumeRatio":0.777189,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BDX.AU","preClose":0.065,"auctionPrice":0.076,"auctionVolume":5071,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020586342}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-50.29%","roe":"-273.29%","lyrEps":-0.02,"volumeRatio":0.777189,"shares":368067640,"dividePrice":0,"high":0.077,"amplitude":0,"preClose":0.07,"low":0.077,"week52Low":0.052,"pbRate":"-34.30","psRate":"12.05","week52High":0.155,"institutionHeld":0,"latestPrice":0.077,"committee":0.962881,"eps":-0.020055,"divideRate":0,"volume":9573,"delay":0,"ttmEps":-0.020055,"open":0.077,"prevYearClose":0.105,"prevWeekClose":0.075,"prevMonthClose":0.066,"prevQuarterClose":0.075,"fiveDayClose":0.076,"twentyDayClose":0.056,"sixtyDayClose":0.081},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"BDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788393600000,"name":null,"time":"","dateTimestamp":1788357600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126786572","title":"BCAL Diagnostics澄清：未與GSS或MAP進行任何併購談判或提案往來","url":"https://stock-news.laohu8.com/highlight/detail?id=1126786572","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126786572?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:22","pubTimestamp":1789010533,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics发布声明，明确表示该公司既未主动提出、也未曾收到任何并购提案，目前亦未与GSS或MAP就合并事宜或其他形式的联合展开任何讨论。这家诊断企业强调，市场上关于其与上述实体进行潜在交易的传言缺乏事实依据。声明措辞简洁而直接，意在消除外界猜测。BCAL Diagnostics的此番表态，似乎是对近期业内传闻的正面回应——传闻曾暗示该公司可能卷入一场涉及同行业者的整合浪潮之中。这种滴水不漏的措辞，无疑是为了杜绝任何解释上的灰色地带。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180507719","title":"BCAL Diagnostics：文中所引述言論源自部分主張三方合併的基金管理人之觀點","url":"https://stock-news.laohu8.com/highlight/detail?id=1180507719","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180507719?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:21","pubTimestamp":1789010474,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics——此前文章中提及的相关评论，实际反映的是部分基金管理人的个人见解，这些基金管理者长期以来一直积极呼吁推动三方合并事宜。\n需要明确的是，这些观点并非公司官方的正式立场。事实上，那些支持三方合并方案的基金经理们，已在多个场合公开表达过他们的倾向性看法。而文章所引用的言论，恰恰来源于这些在幕后持续推动该议程的机构投资者群体。\n在当前的资本运作讨论中，这一细节值得市场参与者给予充分关注，因为它揭示了潜在的利益相关方对未来公司架构演变的不同期待与设想。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173556031","title":"BCAL診斷公司：要求罷免Michael Aicher，並提名Forrester與Melki進入GSS董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1173556031","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173556031?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:42","pubTimestamp":1788403333,"startTime":"0","endTime":"0","summary":"BCAL诊断有限公司已正式提出动议，要求将Michael Aicher从Genetic Signatures Ltd董事会中罢免。与此同时，该公司还力荐Forrester及Melki两位候选人，以期他们能够顺利加入GSS董事会。这一人事调整举措，无疑为GSS公司的治理结构投下了一枚重磅炸弹。BCAL方面显然希望通过此番运作，重塑董事会的权力格局，注入新鲜血液。BCAL此举的深层动因，以及新任董事若顺利上位后将带来怎样的治理新风，均有待市场的进一步观察与解读。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","GSS.AU","BK7048","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115211142","title":"遺傳特徵公司要求BCAL診斷澄清其在GSS的持股及關聯方詳情","url":"https://stock-news.laohu8.com/highlight/detail?id=1115211142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115211142?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 07:39","pubTimestamp":1788392350,"startTime":"0","endTime":"0","summary":"遗传特征有限公司（Genetic Signatures Ltd, GSS.AU）已正式向BCAL诊断有限公司（BCAL Diagnostics Ltd, BDX.AU）发出请求，要求后者就其在该公司的持股情况以及关联方关系提供更为详尽的说明。\n据悉，此项请求涉及BCAL诊断在遗传特征公司中的股东身份及相关联方细节，但具体交易背景及可能引发的后续影响尚未对外披露。市场参与人士正密切关注事态发展，以评估这一动向可能对两家澳大利亚医疗诊断领域企业带来的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7048","GSS.AU","BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182337442","title":"BCAL Diagnostics將收購Genetic Signatures股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1182337442","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182337442?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 16:48","pubTimestamp":1783414100,"startTime":"0","endTime":"0","summary":"7月2日——BCAL Diagnostics有限公司宣布，将收购GENETIC SIGNATURES有限公司的股份。具体而言，BCAL将以139万澳元的价格，收购GENETIC SIGNATURES公司10.2%的股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BDX.AU","GSS.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101703832","title":"BCAL診斷公司與Sonic Healthcare USA或就驗證後的Breastestplus V2版本商談商業許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1101703832","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101703832?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 06:26","pubTimestamp":1779920771,"startTime":"0","endTime":"0","summary":"BCAL诊断公司与Sonic Healthcare USA可能在验证完成后，就第二代Breastestplus产品展开商业许可协议的谈判。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193985776","title":"BCAL Diagnostics Ltd 提交Avantect胰腺癌早期檢測血液測試的MSAC申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1193985776","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193985776?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 06:12","pubTimestamp":1774908740,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics Ltd 已正式向澳大利亚医疗服务咨询委员会（MSAC）提交了关于其Avantect胰腺癌早期检测血液测试的申请。这一关键步骤标志着该公司在推进该创新诊断工具获得官方批准和潜在报销资格方面取得了重要进展。\nAvantect测试旨在通过简单的血液样本实现胰腺癌的早期发现，有望显著改善这种致命疾病的诊断时间线和患者预后。此次MSAC申请的提交是BCAL Diagnostics Ltd商业化战略中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}